360 related articles for article (PubMed ID: 26461489)
1. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
2. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
3. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Roller DG; Capaldo B; Bekiranov S; Mackey AJ; Conaway MR; Petricoin EF; Gioeli D; Weber MJ
Oncotarget; 2016 Jan; 7(3):2734-53. PubMed ID: 26673621
[TBL] [Abstract][Full Text] [Related]
5. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
[TBL] [Abstract][Full Text] [Related]
6. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
7. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
9. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
11. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
12. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
14. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
15. BRAF as a target for cancer therapy.
Dienstmann R; Tabernero J
Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
[TBL] [Abstract][Full Text] [Related]
16. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR; Fridlyand J; Yan Y; Penuel E; Burton L; Chan E; Peng J; Lin E; Wang Y; Sosman J; Ribas A; Li J; Moffat J; Sutherlin DP; Koeppen H; Merchant M; Neve R; Settleman J
Nature; 2012 Jul; 487(7408):505-9. PubMed ID: 22763448
[TBL] [Abstract][Full Text] [Related]
17. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
18. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
20. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
